Apollo-backed Novolex and Pactiv Evergreen to merge in $6.7bn deal
The deal is supported by Apollo, the majority shareholder of Novolex since 2022, and Canada Pension Plan Investment Board.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
